0

Close
 
Upcoming Allied Market Research
2023
Myasthenia Gravis Drugs Market

Myasthenia Gravis Drugs Market: Global Opportunity Analysis and Industry Forecast, 2023-2030 Market

LS : Pharmaceuticals
Report Code: A10457
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Myasthenia Gravis Drugs Market

Request Now !

Myasthenia gravis (MG) is a neuromuscular disease which causes weakness in the skeletal muscles and it occurs when communication between nerve cells and muscles becomes reduced. Myasthenia gravis is characterized by weakness of the head, limb, spinal, eye, and respiratory muscles. In this autoimmune disorder, antibodies are produced against the acetylcholine receptor (AchR) that impedes the normal transmission of electrical signals from nerves to muscles. The muscles is most important part of body which use for movement of body. In myasthenia gravis, immune system produces antibodies that destroy muscles' receptor sites for a neurotransmitter which is known as acetylcholine. With the presence of fewer receptor sites, muscles receive fewer nerve signals, which resulting in weakness in muscles. The development of product such as cholinesterase inhibitors, pyridostigmine medication and neostigmine (Bloxiverz) which increasing the communication between nerves and muscles. Myasthenia gravis occurs more frequently in females than in males, and symptoms may appear at any age, its onset usually peaks in men in their 50s or 60s and in women during their 20s or 30s. But recently, there is no proven therapy for myasthenia gravis, however patients can be treated with medications and surgery for the control the symptoms.

Myasthenia-Gravis-Drugs

COVID-19 Scenario Analysis:

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs.

Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.

The ongoing outbreak of COVID-19 impacted on the growth of myasthenia gravis drugs market and provide opportunities to pharmaceutical industries to developed innovative drug product. Patients with MG and COVID‐19 are highly variable. The manufacturer try to develop new drug product which treat the patient myasthenia gravis disease and COVID-19 as well.  

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis:

Globally, North America hold the largest share of myasthenia gravis drugs market and considered as a most dominating region in this market which attributed to rising awareness of exceptional diseases, increasing development of biologics, and increasing acceptance of immunotherapies & immunosuppressant's. However, Europe is considered as a second largest market share due to the increasing development of technologically advanced drug product which treat the myasthenia gravis disease and rising geriatric population. Whereas Asia-Pacific expected to drive the market growth rate due to the increasing rate of geriatric population and increasing awareness amongst the people regarding treatment 

In 2018, “National Organization for Rare Disorders (NORD)”, reported that about 100,000 individuals suffer from myasthenia gravis each year. This can be attributed to the rising incidence of autoimmune disorders amongst the general public across the world. They also reported that Myasthenia gravis occurs more frequently in females than in males, and although symptoms may appear at any age, its start usually peaks in men in their age of 50s to 60s and in women during their age in 20s or 30s.

The factor that drive the growth of myasthenia gravis drugs market such as Increasing development of novel drugs such as monoclonal antibodies, rising myasthenia gravis and related disorders and increasing patient population across the globe.  Whereas the factor such as increasing competition of generic drug product due to patent loss of several marketed products and availability of cost effective substitutes to branded drugs is restrain the myasthenia gravis drug market growth.

New Product launch to flourish the market:

Major Key market manufacturer have been focusing on producing new product solution for specific applications as there are varying demands based on the utilization. Leading market players have determined how improved accuracy can be influential in many applications. In 2018, “Alexion Pharmaceuticals” and “Astellas Pharma” has launched “Soliris and Prograf”. The drug acts by restricting the disease cells from affecting the immune system. It is used to treat the rare disorders atypical hemolytic uremic syndrome (AHUS) and paroxysmal nocturnal hemoglobinuria (PNH). Recently, this drug is most commonly used to treat the myasthenia gravis disease. In 2018, Novartis' has introduce new monoclonal antibody in the market such as “CFZ-533”. This monoclonal antibody help to produce myasthenia gravis related drug product which help to treat the diseases. Similarly, in 2018, “GlaxoSmithKline's” also introduce new monoclonal antibody such as “Benlysta” which helps to produce effective drug product helps to treat the myasthenia gravis disease. In 2019, “GlaxoSmithKline” has launched new drug product such as “MESTINON”. This drug is useful in the treatment of myasthenia gravis.

Key benefits of the report:

  • This study presents the analytical depiction of the global myasthenia gravis drugs market along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global myasthenia gravis drugs market share.
  • The current market is quantitatively analyzed to highlight the global myasthenia gravis drugs market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed global myasthenia gravis drugs market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the Myasthenia Gravis Drugs Market research report:

  • Who are the leading market players active in myasthenia gravis drugs market?
  • What are the current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What are the projections for the future that will help in taking further strategic steps?

 Myasthenia Gravis Drugs Market: Global Opportunity Analysis and Industry Forecast, 2020–2027 Report Highlights

Aspects Details
By Treatment
  • Medication
  • Surgery
  • Others
By Therapy
  • Anticholinesterases
  • Immunosuppressant’s
  • Intravenous Immune Globulins
By End User
  • Hospitals
  • Clinics
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players F. Hoffmann-La Roche Ltd., Pfizer, Inc., AbbVie Inc., Bausch Health Companies Inc., Avadel Pharmaceuticals plc., Flamel Technologies, Novartis AG, Grifols SA, GlaxoSmithKline plc, Alexion Pharmaceutical Inc.
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: MYASTHENIA GRAVIS DRUGS MARKET, BY TREATMENT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Treatment

    • 4.2. Medication

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Surgery

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Others

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: MYASTHENIA GRAVIS DRUGS MARKET, BY THERAPY

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Therapy

    • 5.2. Anticholinesterases

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Immunosuppressant’s

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Intravenous Immune Globulins

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: MYASTHENIA GRAVIS DRUGS MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Hospitals

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Clinics

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Others

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: MYASTHENIA GRAVIS DRUGS MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Treatment

      • 7.2.3. Market Size and Forecast, By Therapy

      • 7.2.4. Market Size and Forecast, By End User

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Myasthenia Gravis Drugs Market

        • 7.2.6.1. Market Size and Forecast, By Treatment
        • 7.2.6.2. Market Size and Forecast, By Therapy
        • 7.2.6.3. Market Size and Forecast, By End User

      • 7.2.7. Canada Myasthenia Gravis Drugs Market

        • 7.2.7.1. Market Size and Forecast, By Treatment
        • 7.2.7.2. Market Size and Forecast, By Therapy
        • 7.2.7.3. Market Size and Forecast, By End User

      • 7.2.8. Mexico Myasthenia Gravis Drugs Market

        • 7.2.8.1. Market Size and Forecast, By Treatment
        • 7.2.8.2. Market Size and Forecast, By Therapy
        • 7.2.8.3. Market Size and Forecast, By End User

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Treatment

      • 7.3.3. Market Size and Forecast, By Therapy

      • 7.3.4. Market Size and Forecast, By End User

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Myasthenia Gravis Drugs Market

        • 7.3.6.1. Market Size and Forecast, By Treatment
        • 7.3.6.2. Market Size and Forecast, By Therapy
        • 7.3.6.3. Market Size and Forecast, By End User

      • 7.3.7. Germany Myasthenia Gravis Drugs Market

        • 7.3.7.1. Market Size and Forecast, By Treatment
        • 7.3.7.2. Market Size and Forecast, By Therapy
        • 7.3.7.3. Market Size and Forecast, By End User

      • 7.3.8. Italy Myasthenia Gravis Drugs Market

        • 7.3.8.1. Market Size and Forecast, By Treatment
        • 7.3.8.2. Market Size and Forecast, By Therapy
        • 7.3.8.3. Market Size and Forecast, By End User

      • 7.3.9. Spain Myasthenia Gravis Drugs Market

        • 7.3.9.1. Market Size and Forecast, By Treatment
        • 7.3.9.2. Market Size and Forecast, By Therapy
        • 7.3.9.3. Market Size and Forecast, By End User

      • 7.3.10. UK Myasthenia Gravis Drugs Market

        • 7.3.10.1. Market Size and Forecast, By Treatment
        • 7.3.10.2. Market Size and Forecast, By Therapy
        • 7.3.10.3. Market Size and Forecast, By End User

      • 7.3.11. Russia Myasthenia Gravis Drugs Market

        • 7.3.11.1. Market Size and Forecast, By Treatment
        • 7.3.11.2. Market Size and Forecast, By Therapy
        • 7.3.11.3. Market Size and Forecast, By End User

      • 7.3.12. Rest Of Europe Myasthenia Gravis Drugs Market

        • 7.3.12.1. Market Size and Forecast, By Treatment
        • 7.3.12.2. Market Size and Forecast, By Therapy
        • 7.3.12.3. Market Size and Forecast, By End User

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Treatment

      • 7.4.3. Market Size and Forecast, By Therapy

      • 7.4.4. Market Size and Forecast, By End User

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Myasthenia Gravis Drugs Market

        • 7.4.6.1. Market Size and Forecast, By Treatment
        • 7.4.6.2. Market Size and Forecast, By Therapy
        • 7.4.6.3. Market Size and Forecast, By End User

      • 7.4.7. Japan Myasthenia Gravis Drugs Market

        • 7.4.7.1. Market Size and Forecast, By Treatment
        • 7.4.7.2. Market Size and Forecast, By Therapy
        • 7.4.7.3. Market Size and Forecast, By End User

      • 7.4.8. India Myasthenia Gravis Drugs Market

        • 7.4.8.1. Market Size and Forecast, By Treatment
        • 7.4.8.2. Market Size and Forecast, By Therapy
        • 7.4.8.3. Market Size and Forecast, By End User

      • 7.4.9. South Korea Myasthenia Gravis Drugs Market

        • 7.4.9.1. Market Size and Forecast, By Treatment
        • 7.4.9.2. Market Size and Forecast, By Therapy
        • 7.4.9.3. Market Size and Forecast, By End User

      • 7.4.10. Australia Myasthenia Gravis Drugs Market

        • 7.4.10.1. Market Size and Forecast, By Treatment
        • 7.4.10.2. Market Size and Forecast, By Therapy
        • 7.4.10.3. Market Size and Forecast, By End User

      • 7.4.11. Thailand Myasthenia Gravis Drugs Market

        • 7.4.11.1. Market Size and Forecast, By Treatment
        • 7.4.11.2. Market Size and Forecast, By Therapy
        • 7.4.11.3. Market Size and Forecast, By End User

      • 7.4.12. Malaysia Myasthenia Gravis Drugs Market

        • 7.4.12.1. Market Size and Forecast, By Treatment
        • 7.4.12.2. Market Size and Forecast, By Therapy
        • 7.4.12.3. Market Size and Forecast, By End User

      • 7.4.13. Indonesia Myasthenia Gravis Drugs Market

        • 7.4.13.1. Market Size and Forecast, By Treatment
        • 7.4.13.2. Market Size and Forecast, By Therapy
        • 7.4.13.3. Market Size and Forecast, By End User

      • 7.4.14. Rest of Asia Pacific Myasthenia Gravis Drugs Market

        • 7.4.14.1. Market Size and Forecast, By Treatment
        • 7.4.14.2. Market Size and Forecast, By Therapy
        • 7.4.14.3. Market Size and Forecast, By End User

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Treatment

      • 7.5.3. Market Size and Forecast, By Therapy

      • 7.5.4. Market Size and Forecast, By End User

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Myasthenia Gravis Drugs Market

        • 7.5.6.1. Market Size and Forecast, By Treatment
        • 7.5.6.2. Market Size and Forecast, By Therapy
        • 7.5.6.3. Market Size and Forecast, By End User

      • 7.5.7. South Africa Myasthenia Gravis Drugs Market

        • 7.5.7.1. Market Size and Forecast, By Treatment
        • 7.5.7.2. Market Size and Forecast, By Therapy
        • 7.5.7.3. Market Size and Forecast, By End User

      • 7.5.8. Saudi Arabia Myasthenia Gravis Drugs Market

        • 7.5.8.1. Market Size and Forecast, By Treatment
        • 7.5.8.2. Market Size and Forecast, By Therapy
        • 7.5.8.3. Market Size and Forecast, By End User

      • 7.5.9. UAE Myasthenia Gravis Drugs Market

        • 7.5.9.1. Market Size and Forecast, By Treatment
        • 7.5.9.2. Market Size and Forecast, By Therapy
        • 7.5.9.3. Market Size and Forecast, By End User

      • 7.5.10. Argentina Myasthenia Gravis Drugs Market

        • 7.5.10.1. Market Size and Forecast, By Treatment
        • 7.5.10.2. Market Size and Forecast, By Therapy
        • 7.5.10.3. Market Size and Forecast, By End User

      • 7.5.11. Rest of LAMEA Myasthenia Gravis Drugs Market

        • 7.5.11.1. Market Size and Forecast, By Treatment
        • 7.5.11.2. Market Size and Forecast, By Therapy
        • 7.5.11.3. Market Size and Forecast, By End User

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning,2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Alexion Pharmaceutical Inc.

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Grifols SA

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Avadel Pharmaceuticals Plc.

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Novartis AG

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Pfizer, Inc.

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. AbbVie Inc.

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. F. Hoffmann-La Roche Ltd.

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. GlaxoSmithKline Plc

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Bausch Health Companies Inc.

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Flamel Technologies

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL MYASTHENIA GRAVIS DRUGS MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL MYASTHENIA GRAVIS DRUGS MARKET FOR MEDICATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL MYASTHENIA GRAVIS DRUGS MARKET FOR SURGERY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL MYASTHENIA GRAVIS DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL MYASTHENIA GRAVIS DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL MYASTHENIA GRAVIS DRUGS MARKET FOR ANTICHOLINESTERASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL MYASTHENIA GRAVIS DRUGS MARKET FOR IMMUNOSUPPRESSANT’S, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL MYASTHENIA GRAVIS DRUGS MARKET FOR INTRAVENOUS IMMUNE GLOBULINS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL MYASTHENIA GRAVIS DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL MYASTHENIA GRAVIS DRUGS MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL MYASTHENIA GRAVIS DRUGS MARKET FOR CLINICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL MYASTHENIA GRAVIS DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL MYASTHENIA GRAVIS DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA MYASTHENIA GRAVIS DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA MYASTHENIA GRAVIS DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA MYASTHENIA GRAVIS DRUGS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA MYASTHENIA GRAVIS DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 18. U.S. MYASTHENIA GRAVIS DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 19. U.S. MYASTHENIA GRAVIS DRUGS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 20. U.S. MYASTHENIA GRAVIS DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 21. CANADA MYASTHENIA GRAVIS DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 22. CANADA MYASTHENIA GRAVIS DRUGS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 23. CANADA MYASTHENIA GRAVIS DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO MYASTHENIA GRAVIS DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO MYASTHENIA GRAVIS DRUGS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO MYASTHENIA GRAVIS DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE MYASTHENIA GRAVIS DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE MYASTHENIA GRAVIS DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE MYASTHENIA GRAVIS DRUGS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE MYASTHENIA GRAVIS DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 31. FRANCE MYASTHENIA GRAVIS DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 32. FRANCE MYASTHENIA GRAVIS DRUGS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 33. FRANCE MYASTHENIA GRAVIS DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 34. GERMANY MYASTHENIA GRAVIS DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 35. GERMANY MYASTHENIA GRAVIS DRUGS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 36. GERMANY MYASTHENIA GRAVIS DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 37. ITALY MYASTHENIA GRAVIS DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 38. ITALY MYASTHENIA GRAVIS DRUGS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 39. ITALY MYASTHENIA GRAVIS DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 40. SPAIN MYASTHENIA GRAVIS DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 41. SPAIN MYASTHENIA GRAVIS DRUGS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 42. SPAIN MYASTHENIA GRAVIS DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 43. UK MYASTHENIA GRAVIS DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 44. UK MYASTHENIA GRAVIS DRUGS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 45. UK MYASTHENIA GRAVIS DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 46. RUSSIA MYASTHENIA GRAVIS DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 47. RUSSIA MYASTHENIA GRAVIS DRUGS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 48. RUSSIA MYASTHENIA GRAVIS DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 49. REST OF EUROPE MYASTHENIA GRAVIS DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 50. REST OF EUROPE MYASTHENIA GRAVIS DRUGS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 51. REST OF EUROPE MYASTHENIA GRAVIS DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC MYASTHENIA GRAVIS DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 53. ASIA-PACIFIC MYASTHENIA GRAVIS DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 54. ASIA-PACIFIC MYASTHENIA GRAVIS DRUGS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 55. ASIA-PACIFIC MYASTHENIA GRAVIS DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 56. CHINA MYASTHENIA GRAVIS DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 57. CHINA MYASTHENIA GRAVIS DRUGS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 58. CHINA MYASTHENIA GRAVIS DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 59. JAPAN MYASTHENIA GRAVIS DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 60. JAPAN MYASTHENIA GRAVIS DRUGS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 61. JAPAN MYASTHENIA GRAVIS DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 62. INDIA MYASTHENIA GRAVIS DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 63. INDIA MYASTHENIA GRAVIS DRUGS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 64. INDIA MYASTHENIA GRAVIS DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA MYASTHENIA GRAVIS DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA MYASTHENIA GRAVIS DRUGS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA MYASTHENIA GRAVIS DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 68. AUSTRALIA MYASTHENIA GRAVIS DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 69. AUSTRALIA MYASTHENIA GRAVIS DRUGS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 70. AUSTRALIA MYASTHENIA GRAVIS DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 71. THAILAND MYASTHENIA GRAVIS DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 72. THAILAND MYASTHENIA GRAVIS DRUGS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 73. THAILAND MYASTHENIA GRAVIS DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 74. MALAYSIA MYASTHENIA GRAVIS DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 75. MALAYSIA MYASTHENIA GRAVIS DRUGS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 76. MALAYSIA MYASTHENIA GRAVIS DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 77. INDONESIA MYASTHENIA GRAVIS DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 78. INDONESIA MYASTHENIA GRAVIS DRUGS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 79. INDONESIA MYASTHENIA GRAVIS DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 80. REST OF ASIA PACIFIC MYASTHENIA GRAVIS DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 81. REST OF ASIA PACIFIC MYASTHENIA GRAVIS DRUGS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC MYASTHENIA GRAVIS DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 83. LAMEA MYASTHENIA GRAVIS DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 84. LAMEA MYASTHENIA GRAVIS DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 85. LAMEA MYASTHENIA GRAVIS DRUGS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 86. LAMEA MYASTHENIA GRAVIS DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 87. BRAZIL MYASTHENIA GRAVIS DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 88. BRAZIL MYASTHENIA GRAVIS DRUGS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 89. BRAZIL MYASTHENIA GRAVIS DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 90. SOUTH AFRICA MYASTHENIA GRAVIS DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 91. SOUTH AFRICA MYASTHENIA GRAVIS DRUGS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 92. SOUTH AFRICA MYASTHENIA GRAVIS DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 93. SAUDI ARABIA MYASTHENIA GRAVIS DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 94. SAUDI ARABIA MYASTHENIA GRAVIS DRUGS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 95. SAUDI ARABIA MYASTHENIA GRAVIS DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 96. UAE MYASTHENIA GRAVIS DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 97. UAE MYASTHENIA GRAVIS DRUGS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 98. UAE MYASTHENIA GRAVIS DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 99. ARGENTINA MYASTHENIA GRAVIS DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 100. ARGENTINA MYASTHENIA GRAVIS DRUGS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 101. ARGENTINA MYASTHENIA GRAVIS DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 102. REST OF LAMEA MYASTHENIA GRAVIS DRUGS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 103. REST OF LAMEA MYASTHENIA GRAVIS DRUGS, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 104. REST OF LAMEA MYASTHENIA GRAVIS DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 105. ALEXION PHARMACEUTICAL INC.: KEY EXECUTIVES
  • TABLE 106. ALEXION PHARMACEUTICAL INC.: COMPANY SNAPSHOT
  • TABLE 107. ALEXION PHARMACEUTICAL INC.: OPERATING SEGMENTS
  • TABLE 108. ALEXION PHARMACEUTICAL INC.: PRODUCT PORTFOLIO
  • TABLE 109. ALEXION PHARMACEUTICAL INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 110. GRIFOLS SA: KEY EXECUTIVES
  • TABLE 111. GRIFOLS SA: COMPANY SNAPSHOT
  • TABLE 112. GRIFOLS SA: OPERATING SEGMENTS
  • TABLE 113. GRIFOLS SA: PRODUCT PORTFOLIO
  • TABLE 114. GRIFOLS SA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 115. AVADEL PHARMACEUTICALS PLC.: KEY EXECUTIVES
  • TABLE 116. AVADEL PHARMACEUTICALS PLC.: COMPANY SNAPSHOT
  • TABLE 117. AVADEL PHARMACEUTICALS PLC.: OPERATING SEGMENTS
  • TABLE 118. AVADEL PHARMACEUTICALS PLC.: PRODUCT PORTFOLIO
  • TABLE 119. AVADEL PHARMACEUTICALS PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 120. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 121. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 122. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 123. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 124. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 125. PFIZER, INC.: KEY EXECUTIVES
  • TABLE 126. PFIZER, INC.: COMPANY SNAPSHOT
  • TABLE 127. PFIZER, INC.: OPERATING SEGMENTS
  • TABLE 128. PFIZER, INC.: PRODUCT PORTFOLIO
  • TABLE 129. PFIZER, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 130. ABBVIE INC.: KEY EXECUTIVES
  • TABLE 131. ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 132. ABBVIE INC.: OPERATING SEGMENTS
  • TABLE 133. ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 134. ABBVIE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 135. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 136. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 137. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
  • TABLE 138. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 139. F. HOFFMANN-LA ROCHE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 140. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 141. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 142. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 143. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 144. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 145. BAUSCH HEALTH COMPANIES INC.: KEY EXECUTIVES
  • TABLE 146. BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT
  • TABLE 147. BAUSCH HEALTH COMPANIES INC.: OPERATING SEGMENTS
  • TABLE 148. BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO
  • TABLE 149. BAUSCH HEALTH COMPANIES INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 150. FLAMEL TECHNOLOGIES: KEY EXECUTIVES
  • TABLE 151. FLAMEL TECHNOLOGIES: COMPANY SNAPSHOT
  • TABLE 152. FLAMEL TECHNOLOGIES: OPERATING SEGMENTS
  • TABLE 153. FLAMEL TECHNOLOGIES: PRODUCT PORTFOLIO
  • TABLE 154. FLAMEL TECHNOLOGIES: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL MYASTHENIA GRAVIS DRUGS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL MYASTHENIA GRAVIS DRUGS MARKET
  • FIGURE 3. SEGMENTATION MYASTHENIA GRAVIS DRUGS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN MYASTHENIA GRAVIS DRUGS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALMYASTHENIA GRAVIS DRUGS MARKET
  • FIGURE 11. MYASTHENIA GRAVIS DRUGS MARKET SEGMENTATION, BY BY TREATMENT
  • FIGURE 12. MYASTHENIA GRAVIS DRUGS MARKET FOR MEDICATION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. MYASTHENIA GRAVIS DRUGS MARKET FOR SURGERY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. MYASTHENIA GRAVIS DRUGS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. MYASTHENIA GRAVIS DRUGS MARKET SEGMENTATION, BY BY THERAPY
  • FIGURE 16. MYASTHENIA GRAVIS DRUGS MARKET FOR ANTICHOLINESTERASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. MYASTHENIA GRAVIS DRUGS MARKET FOR IMMUNOSUPPRESSANT’S, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. MYASTHENIA GRAVIS DRUGS MARKET FOR INTRAVENOUS IMMUNE GLOBULINS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. MYASTHENIA GRAVIS DRUGS MARKET SEGMENTATION, BY BY END USER
  • FIGURE 20. MYASTHENIA GRAVIS DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. MYASTHENIA GRAVIS DRUGS MARKET FOR CLINICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. MYASTHENIA GRAVIS DRUGS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 24. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 25. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 26. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 27. COMPETITIVE DASHBOARD
  • FIGURE 28. COMPETITIVE HEATMAP: MYASTHENIA GRAVIS DRUGS MARKET
  • FIGURE 29. Top player positioning, 2022
  • FIGURE 30. ALEXION PHARMACEUTICAL INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 31. ALEXION PHARMACEUTICAL INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 32. ALEXION PHARMACEUTICAL INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 33. GRIFOLS SA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 34. GRIFOLS SA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 35. GRIFOLS SA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 36. AVADEL PHARMACEUTICALS PLC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. AVADEL PHARMACEUTICALS PLC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. AVADEL PHARMACEUTICALS PLC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. NOVARTIS AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. PFIZER, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. PFIZER, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. PFIZER, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. ABBVIE INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. ABBVIE INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. ABBVIE INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 54. BAUSCH HEALTH COMPANIES INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. BAUSCH HEALTH COMPANIES INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 56. BAUSCH HEALTH COMPANIES INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 57. FLAMEL TECHNOLOGIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. FLAMEL TECHNOLOGIES: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 59. FLAMEL TECHNOLOGIES: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Myasthenia Gravis Drugs Market

Start reading.
This Report and over 66,905+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers